Awaiting 2012 Clinical Data Readout
Merck Hands Idera Global Rights to IMO-2055 in Cancer
By Marie Powers
Thursday, December 1, 2011
Merck KGaA has returned global rights to IMO-2055, a TLR9 agonist, as a cancer therapy to partner Idera Pharmaceuticals Inc. following the termination of their oncology collaboration.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.